These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38825630)

  • 21. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
    Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
    Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.
    Deng Y; Zhao Q; Gong R
    Diabetes Metab Syndr Obes; 2021; 14():1751-1761. PubMed ID: 33911888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fat tissue quantity, waist circumference or waist-to-hip ratio in patients with chronic kidney disease: A systematic review and meta-analysis.
    Zimmermann S; Mathew A; Schöppe R; Mangova G; Biemann R; Surov A; Meyer HJ; Isermann B
    Obes Res Clin Pract; 2024; 18(2):81-87. PubMed ID: 38582736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
    Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
    Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
    Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
    Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018.
    Zhang Y; Zhang M; Jiang S; Hu H; Wang X; Yu F; Huang Y; Liang Y
    Cancer Causes Control; 2024 Sep; 35(9):1271-1282. PubMed ID: 38764062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynapenic-abdominal obesity as an independent risk factor for chronic kidney disease in postmenopausal women: a population-based cohort study.
    Choi Y; Cho J; Kim J; Bae JH; Cho EJ; Chang E; Joa KL; Kim J; Park DH; Kang JH; Kwak HB
    Menopause; 2022 Sep; 29(9):1040-1046. PubMed ID: 36040432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
    Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
    Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Stiffness With Bone Mineral Density in American Adults.
    Li H; Luo H; Zhang Y; Liu L; Lin R
    Front Endocrinol (Lausanne); 2022; 13():891382. PubMed ID: 35846319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study.
    Lee GB; Huh Y; Lee SH; Han B; Kim YH; Kim DH; Kim SM; Choi YS; Cho KH; Nam GE
    World J Gastroenterol; 2023 Dec; 29(45):5962-5973. PubMed ID: 38131000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
    Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
    Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study.
    Farrell AM; Magliano DJ; Shaw JE; Thompson AJ; Croagh C; Ryan MC; Howell J
    Sci Rep; 2022 Feb; 12(1):1956. PubMed ID: 35121749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
    Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
    Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
    Hashimoto Y; Hamaguchi M; Okamura T; Nakanishi N; Obora A; Kojima T; Fukui M
    J Diabetes Investig; 2022 Feb; 13(2):308-316. PubMed ID: 34561962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
    Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
    Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Serum Ferritin Levels and Metabolic-associated Fatty Liver Disease in Adults: a Cross-sectional Study Based on the NHANES.
    Li JH; Ma XY; Yi Y; Li LR; Xu ZY; Chang Y
    Curr Med Sci; 2024 Jun; 44(3):494-502. PubMed ID: 38748368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and its relation to chronic kidney disease: a population-based, cross-sectional study of a Thai army population and relatives.
    Satirapoj B; Supasyndh O; Mayteedol N; Punpanich D; Chaiprasert A; Nata N; Ruangkanchanasetr P; Kanjanakul I; Choovichian P
    Nephrology (Carlton); 2013 Mar; 18(3):229-34. PubMed ID: 23279639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.